Skip to main content
Premium Trial:

Request an Annual Quote

Cytek Biosciences Closes $120M Series D Financing Round

NEW YORK — Flow cytometry instrument developer Cytek Biosciences said on Thursday that it has raised $120 million in a Series D financing round.

The round was led by RA Capital and Hillhouse Capital with participation from OrbiMed and Lyfe Capital.

Cytek said that it will use the funding to expand its global infrastructure, as well as to expand its presence in the cell-analysis market in areas such as immunotherapy, immuno-oncology, and infectious disease.

In conjunction with the round, members of RA Capital and Hillhouse Capital have joined Cytek's board of directors.

In August, Cytek launched its cFluor line of reagents for its Aurora and Northern Lights cytometry systems. About a year ago, the Fremont, California-based company updated the Aurora instrument, which it said can run beyond 40-color panels.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.